NASDAQ:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis → America’s worst nightmare? (From Porter & Company) (Ad) Free LOGC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.44▼$5.8550-Day Range$2.04▼$2.0752-Week Range$0.26▼$3.77Volume691,751 shsAverage Volume652,526 shsMarket Capitalization$182.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsInsider TradesOptions ChainSocial MediaSustainabilityStock AnalysisCompetitorsInsider TradesOptions ChainSocial MediaSustainability Get LogicBio Therapeutics alerts: Email Address Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About LogicBio Therapeutics Stock (NASDAQ:LOGC)LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. LOGC Stock News HeadlinesMay 14 at 3:21 AM | finance.yahoo.comLogicBio Therapeutics, Inc. (LOGC)March 27, 2024 | seekingalpha.comRVVTF Revive Therapeutics Ltd.September 24, 2023 | finance.yahoo.comLogicBio's IPO: What You Need To KnowMarch 31, 2023 | uk.finance.yahoo.comRare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports LtdNovember 16, 2022 | finance.yahoo.comAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® TherapeuticsNovember 14, 2022 | finanznachrichten.deLogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 14, 2022 | finance.yahoo.comLogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 7, 2022 | benzinga.comShort Volatility Alert: LogicBio Therapeutics, Inc.October 17, 2022 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTXOctober 4, 2022 | benzinga.comINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGCOctober 3, 2022 | msn.comLooking Into LogicBio Therapeutics's Recent Short InterestOctober 3, 2022 | marketwatch.comLogicBio Therapeutics Shares Soar on Takeover by AstraZeneca >LOGCOctober 3, 2022 | bizjournals.comAstraZeneca acquires local startup at 660% premiumOctober 3, 2022 | finance.yahoo.comLogicBio's stock skyrockets after buyout bid for a 667% premiumOctober 3, 2022 | msn.comAstraZeneca pays 660% premium for gene therapy firm LogicBioOctober 3, 2022 | nasdaq.comLogicBio To Be Bought By Alexion, AstraZeneca Rare DiseaseOctober 3, 2022 | marketwatch.comAstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGCOctober 3, 2022 | msn.comWhy LogicBio Therapeutics Stock Is Soaring TodayOctober 3, 2022 | finance.yahoo.comAlexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic MedicineSeptember 21, 2022 | finance.yahoo.comLogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONESeptember 1, 2022 | reuters.comLogicBio Therapeutics IncAugust 18, 2022 | finance.yahoo.comEarnings Update: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported And Analysts Are Boosting Their EstimatesAugust 16, 2022 | benzinga.comRecap: LogicBio Therapeutics Q2 EarningsJuly 27, 2022 | finance.yahoo.comLogicBio Therapeutics (LOGC) Moves to Buy: Rationale Behind the UpgradeJune 14, 2022 | morningstar.comLogicBio Therapeutics Inc - Stock Quote LOGCSee More Headlines Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/14/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LOGC CUSIPN/A CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,030,000.00 Net Margins-246.71% Pretax Margin-246.71% Return on Equity-115.29% Return on Assets-53.01% Debt Debt-to-Equity Ratio0.17 Current Ratio1.99 Quick Ratio2.26 Sales & Book Value Annual Sales$5.41 million Price / Sales33.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book11.56Miscellaneous Outstanding Shares32,963,000Free Float30,293,000Market Cap$182.94 million OptionableOptionable Beta4.61 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Frederic Chereau M.B.A. (Age 55)Pres, CEO & Director Comp: $793.2kDr. Mark A. Kay M.D. (Age 64)Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $107.5kDr. Daniel J. Gruskin M.D. (Age 50)Chief Medical Officer Comp: $577.48kDr. Leszek Lisowski M.B.A.Ph.D., Co-Founder & Member of Scientific Advisory BoardDr. Adi Barzel Ph.D.Co-FounderMr. Joshua Blacher (Age 49)Interim CFO, Principal Financial Officer & Principal Accounting Officer Dr. Matthias Hebben Ph.D.Global VP & Head of Technology Devel.Dr. Mariana Nacht Ph.D. (Age 58)Chief Scientific Officer Ms. Andrea Paul J.D. (Age 41)Gen. Counsel & Corp. Sec. Ms. Grace LochheadVP & Head of HRMore ExecutivesKey CompetitorsIkena OncologyNASDAQ:IKNATurnstone BiologicsNASDAQ:TSBXElutiaNASDAQ:ELUTAtara BiotherapeuticsNASDAQ:ATRAInstil BioNASDAQ:TILView All Competitors LOGC Stock Analysis - Frequently Asked Questions When is LogicBio Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our LOGC earnings forecast. How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (NASDAQ:LOGC) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.01. The business had revenue of $2.12 million for the quarter, compared to analyst estimates of $5.02 million. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 115.29% and a negative net margin of 246.71%. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), Acceleron Pharma (XLRN), Stoke Therapeutics (STOK), Precision BioSciences (DTIL), Micron Technology (MU), Homology Medicines (FIXX) and II-VI (IIVI). When did LogicBio Therapeutics IPO? LogicBio Therapeutics (LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager. This page (NASDAQ:LOGC) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressElon to Transform U.S. Economy? Porter & CompanyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.